Novartis AG
NVSEF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $14,358,000 | $14,836,000 | $13,620,000 | $13,558,000 |
| % Growth | -3.2% | 8.9% | 0.5% | – |
| Cost of Goods Sold | $3,539,000 | $3,322,000 | $3,227,000 | $3,324,000 |
| Gross Profit | $10,819,000 | $11,514,000 | $10,393,000 | $10,234,000 |
| % Margin | 75.4% | 77.6% | 76.3% | 75.5% |
| R&D Expenses | $2,944,000 | $2,727,000 | $2,366,000 | $2,842,000 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $3,308,000 | $3,442,000 | $3,058,000 | $3,501,000 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $66,000 | $481,000 | $306,000 | $361,000 |
| Operating Expenses | $6,318,000 | $6,650,000 | $5,730,000 | $6,704,000 |
| Operating Income | $4,501,000 | $4,864,000 | $4,654,068 | $3,530,000 |
| % Margin | 31.3% | 32.8% | 34.2% | 26% |
| Other Income/Exp. Net | -$305,000 | -$333,000 | -$175,683 | -$245,000 |
| Pre-Tax Income | $4,196,000 | $4,531,000 | $4,478,385 | $3,285,000 |
| Tax Expense | $266,000 | $507,000 | $810,374 | $465,000 |
| Net Income | $3,928,000 | $4,041,000 | $3,661,918 | $2,818,000 |
| % Margin | 27.4% | 27.2% | 26.9% | 20.8% |
| EPS | 2.02 | 2.07 | 1.83 | 1.42 |
| % Growth | -2.4% | 13.1% | 28.9% | – |
| EPS Diluted | 2 | 2.06 | 1.82 | 1.41 |
| Weighted Avg Shares Out | 1,948,000 | 1,948,000 | 1,968,000 | 1,987,000 |
| Weighted Avg Shares Out Dil | 1,960,000 | 1,960,000 | 1,979,000 | 2,004,000 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $291,000 |
| Interest Expense | $281,000 | $300,864 | $274,187 | $275,000 |
| Depreciation & Amortization | $1,364,000 | $1,256,000 | $1,154,000 | $1,628,000 |
| EBITDA | $5,841,000 | $6,076,000 | $5,831,000 | $5,188,000 |
| % Margin | 40.7% | 41% | 42.8% | 38.3% |